Cointime

Vedere Bio ll

company

About

Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.

  • 1 - 10

Highlights

Total Funding Amount
$98M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$77M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jun 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$98M
Vedere Bio ll has raised a total of $98M in funding over 2 rounds. Their latest funding was raised on May 18, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 18, 2021 Series A $77M 1 — — Detail
Jun 1, 2019 Series A $21M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Vedere Bio ll is funded by 2 investors. Retinal Degeneration Fund and Foundation Fighting Blindness are the most recent investors.
Investor Name Lead Investor Funding Round
Retinal Degeneration Fund — Series A
Foundation Fighting Blindness — Series A
Cointime
İçerikler
Şirket.